Open label study of ONTAK (denileukin diftitox, DAB389IL-2) to estimate response in cutaneous T-cell lymphoma (CTCL) according to CD25 status.
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2009
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- Sponsors Ligand Pharmaceuticals
- 09 Sep 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
- 22 May 2007 Status changed from in progress
- 11 Feb 2006 New trial record.